Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth-Reference-Cited by-同舟云学术

Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth

Published:2005-07 Issue:1 Volume:22 Page:31-35
ISSN:0269-2813
Container-title:Alimentary Pharmacology and Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

LAURITANO E. C.,GABRIELLI M.,LUPASCU A.,SANTOLIQUIDO A.,NUCERA G.,SCARPELLINI E.,VINCENTI F.,CAMMAROTA G.,FLORE R.,POLA P.,GASBARRINI G.,GASBARRINI A.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2005.02516.x/fullpdf

Reference15 articles.

1. Small bowel bacterial overgrowth: Presentation, diagnosis, and treatment

2. Breath hydrogen testing in bacterial overgrowth of the small intestine

3. Reply

4. The diagnosis of small bowel bacterial overgrowth

5. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical appraisal of the SIBO hypothesis and breath testing: A clinical practice update endorsed by the European society of neurogastroenterology and motility (ESNM) and the American neurogastroenterology and motility society (ANMS);Neurogastroenterology & Motility;2024-05-26

2. Effect of Trimebutine and Rifaximin on Breath Hydrogen and Methane by Glucose Breath Test in Patients With Functional Bloating: A Randomized Double-blind Clinical Trial;Journal of Neurogastroenterology and Motility;2024-04-30

3. Intestinal microbiota regulates the gut-thyroid axis: the new dawn of improving Hashimoto thyroiditis;Clinical and Experimental Medicine;2024-02-22

4. An Overview of Short-Bowel Syndrome in Pediatric Patients: Focus on Clinical Management and Prevention of Complications;Nutrients;2023-05-17

5. Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase Ⅱa exploratory trial;Bioscience of Microbiota, Food and Health;2023